Edesa Biotech Inc. has filed a prospectus supplement with the U.S. Securities and Exchange Commission for an "at the market offering" program. This program allows the company to offer and sell up to $4,006,544 worth of its common shares through H.C. Wainwright & Co., LLC, acting as the sales agent. The company has already sold $837,134 worth of these shares under the existing agreement. The offering will be conducted under a shelf registration statement declared effective by the SEC, with legal opinion from Fasken Martineau DuMoulin LLP confirming the validity of the shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005800), on September 09, 2025, and is solely responsible for the information contained therein.